Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Treatment-free remission in patients with chronic myeloid leukemia following the second discontinuation of tyrosine kinase inhibitors

Yingling Zu, HUIFANG ZHAO, Yongping Song, Bingcheng LIU, Li Weiming, Qian Jiang, Yanli Zhang

Blood (2025) 146 (Supplement 1): 7302.

https://doi.org/10.1182/blood-2025-7302

Published: 2025

Journal Articles

Antiviral efficacy of EBV and CMV bispecific cytotoxic t lymphocytes following allogeneic hematopoietic stem cell transplantation

Ruirui Gui, Zhen Li, juan wang, wenli Zhang, xiangke xin, Yingling Zu, dingjie li, Xianjing Wang, huili wang, Baijun Fang, Yongping Song, Jian Zhou

Blood (2025) 146 (Supplement 1): 7646.

https://doi.org/10.1182/blood-2025-7646

Published: 2025

Journal Articles

First-line treatment with low-dose ruxolitinib, pirfenidone, and low-dose calcineurin inhibitors leads to significant improvement in patients with bronchiolitis obliterans syndrome after allogeneic transplantation

Zhen Li, Ruirui Gui, juan wang, wenli Zhang, Yongping Song, Xudong Li, Binglei Zhang, Jian Zhou

Blood (2025) 146 (Supplement 1): 7828.

https://doi.org/10.1182/blood-2025-7828

Published: 2025

Journal Articles

FBXO3-mediated DUSP9 ubiquitination reprograms MAPK signaling to eradicate tyrosine kinase inhibitor-resistant CML stem cells

Xudong Li, Shiyu Zuo, Binglei Zhang, zhenghua huang, ruochen xu, mengjia li, Hong Huang, Yaomei Wang, Yongping Song, Baijun Fang, Bian Zhilei, Wei Li

Blood (2025) 146 (Supplement 1): 3754.

https://doi.org/10.1182/blood-2025-3754

Published: 2025

Journal Articles

Beyond the unknown: Leveraging machine learning to predict adverse outcomes in pregnant women with aplastic anemia from a representative nationwide cohort

Blood (2025) 146 (Supplement 1): 1413.

https://doi.org/10.1182/blood-2025-1413

Published: 2025

Journal Articles

Interim results of a multi-center clinical trial evaluating copy number aberrations via shallow whole-genome sequencing (LeukoPrint) in Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 5245.

https://doi.org/10.1182/blood-2025-5245

Published: 2025

Journal Articles

Treatment patterns and survival outcomes after immunotherapy failure in patients with NK/T cell lymphoma: A multicenter retrospective study

Yuchen Zhang, Qingqing Cai, Yongping Song, Yexiong Li, Shunan Qi, Yi Xia, Shenrui Bai, Jun Cai, Bing BAI, Xiaojie Fang, Man Nie, Yi Cao

Blood (2025) 146 (Supplement 1): 3643.

https://doi.org/10.1182/blood-2025-3643

Published: 2025

Journal Articles

Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-Phase chronic myeloid leukemia (CML-CP) in a registrational randomized Phase 2 trial: Up to 4-year follow-up including patients without T315I mutations

Blood (2025) 146 (Supplement 1): 3788.

https://doi.org/10.1182/blood-2025-3788

Published: 2025

Journal Articles

Combined Low-Dose TBI, Ivig, and DEX for Donor-Specific Antibody Desensitization in Haploidentical and Mmud Haematopoietic Stem Cell Transplantation： a Retrospective Multicenter Case-Control Study

Blood (2024) 144 (Supplement 1): 7104.

https://doi.org/10.1182/blood-2024-204549

Published: 2024

Journal Articles

The Impact of Anti-HLA Antibodies on the Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome

Tiantian Xie, Runqing Lu, Weijie Cao, Bian Zhilei, Wei Li, Zhongxing Jiang, Yongping Song, Dengju Li, Rong Guo

Blood (2024) 144 (Supplement 1): 7419.

https://doi.org/10.1182/blood-2024-206974

Published: 2024

Journal Articles

Decoding the Immune Microenvironment of Primary Chronic Myelomonocytic Leukemia and Secondary Chronic Myelomonocytic Leukemia Due to DLBCL with CD19 CAR-T Failure By Single-Cell RNA-Seq

Xudong Li, Hong Huang, Binglei Zhang, Zhongxing Jiang, Yongping Song, Wenyi Lu, Bian Zhilei, Wei Li, Weijie Cao

Blood (2024) 144 (Supplement 1): 6695.

https://doi.org/10.1182/blood-2024-201202

Published: 2024

Journal Articles

Tyrosine Kinase Inhibitors Short Exposure in Pregnant Female Patients with Chronic Myeloid Leukemia

Yingling Zu, Huifang Zhao, Jianling Chen, Huibing Dang, Yanrong Shi, Lixin Liang, Shuhao Mei, Wenyi Lu, Jian Zhou, Yongping Song, Yanli Zhang

Blood (2024) 144 (Supplement 1): 1775.

https://doi.org/10.1182/blood-2024-206494

Published: 2024

Journal Articles

Updated Results from a Phase I Trial of Amulirafusp Alfa (IMM0306) in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma

Yuankai Shi, Jianliang Yang, Yongping Song, Keshu Zhou, Zhiming Li, Mingzhi Zhang, Hongmei Jing, Zhen Wang, Li Yu, Wei Meng, Qiying Lu, Wenzhi Tian

Blood (2024) 144 (Supplement 1): 1632.

https://doi.org/10.1182/blood-2024-200499

Published: 2024

Journal Articles

Efficacy and Safety of Carfilzomib-Based Regimens in Multiple Myeloma: Single-Center Real-World Experience

Yaomei Wang, Xueting Wang, Yuzhang Liu, Lijie Liang, Lina Liu, Wenyi Lu, Yongping Song, Baijun Fang

Blood (2024) 144 (Supplement 1): 7836.

https://doi.org/10.1182/blood-2024-206491

Published: 2024

Journal Articles

Preliminary Results of Patients with Myelofibrosis (MF) from a Phase I Trial of Jab-8263, a Potent BET Inhibitor

Junyuan Qi, Bo Jiang, Wei Yang, Xudong Wei, Hongmei Jing, Yongping Song, Andrea Wang-Gillam, Yuli Ding, Chao Bi, Ting Zhang

Blood (2024) 144 (Supplement 1): 4567.

https://doi.org/10.1182/blood-2024-209977

Published: 2024

Journal Articles

Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China

Blood (2024) 144 (Supplement 1): 4196.

https://doi.org/10.1182/blood-2024-199983

Published: 2024

Journal Articles

Humanized Monoclonal Antibody IMM47, Targeting CD24, Exhibits Exceptional Anti-Tumor Efficacy By Blocking the CD24/Siglec-10 Interaction and Can be Used As Monotherapy or in Combination with Anti-PD1 Antibodies for Cancer Immunotherapy

Jifeng Yu, Song Li, Dianze Chen, Huiqin Guo, Yanan Yang, Dandan Liu, Chunmei Yang, Xing Bai, Wei Zhang, Li Zhang, Gui Zhao, Xiaoping Tu, Liang Peng, Sijin Liu, Yongping Song, Zhongxing Jiang, Ruliang Zhang, Wenzhi Tian

Blood (2023) 142 (Supplement 1): 7140.

https://doi.org/10.1182/blood-2023-172483

Published: 2023

Journal Articles

ZGGS15, a Novel IgG4 Bispecific Monoclonal Antibody Targeting Both LAG-3 and Tigit, Demonstrates Outstanding Anti-Tumor Activity and Can be Used As Monotherapy or in Combination with Anti-PD-1 Antibodies for Cancer Immunotherapy

Jifeng Yu, Tongcheng Dai, Hao Sun, Bin Zhang, Tyler Liban, Jessica Ochoa, Jackie Sheng, Yongping Song, Zhongxing Jiang, Zelin Sheng, Binhua Lv

Blood (2023) 142 (Supplement 1): 5764.

https://doi.org/10.1182/blood-2023-184775

Published: 2023

Journal Articles

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Blood (2023) 142 (Supplement 1): 869.

https://doi.org/10.1182/blood-2023-187740

Published: 2023

Journal Articles

Heritable SETBP1 Mutations Associated with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Jingyi Yang, Shanlan Mo, Xudong Wei, Xiaodong Lv, Ya Zhang, Yuewen Fu, Baijun Fang, Yanli Zhang, Jian Zhou, Hu Zhou, Quande Lin, Delong Liu, Yongping Song, Qianfei Wang, Keshu Zhou

Blood (2023) 142 (Supplement 1): 5684.

https://doi.org/10.1182/blood-2023-182788

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Treatment-free remission in patients with chronic myeloid leukemia following the second discontinuation of tyrosine kinase inhibitors

Antiviral efficacy of EBV and CMV bispecific cytotoxic t lymphocytes following allogeneic hematopoietic stem cell transplantation

First-line treatment with low-dose ruxolitinib, pirfenidone, and low-dose calcineurin inhibitors leads to significant improvement in patients with bronchiolitis obliterans syndrome after allogeneic transplantation

FBXO3-mediated DUSP9 ubiquitination reprograms MAPK signaling to eradicate tyrosine kinase inhibitor-resistant CML stem cells

Beyond the unknown: Leveraging machine learning to predict adverse outcomes in pregnant women with aplastic anemia from a representative nationwide cohort

Interim results of a multi-center clinical trial evaluating copy number aberrations via shallow whole-genome sequencing (LeukoPrint) in Acute Myeloid Leukemia

Treatment patterns and survival outcomes after immunotherapy failure in patients with NK/T cell lymphoma: A multicenter retrospective study

Combined Low-Dose TBI, Ivig, and DEX for Donor-Specific Antibody Desensitization in Haploidentical and Mmud Haematopoietic Stem Cell Transplantation： a Retrospective Multicenter Case-Control Study

The Impact of Anti-HLA Antibodies on the Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome

Decoding the Immune Microenvironment of Primary Chronic Myelomonocytic Leukemia and Secondary Chronic Myelomonocytic Leukemia Due to DLBCL with CD19 CAR-T Failure By Single-Cell RNA-Seq

Tyrosine Kinase Inhibitors Short Exposure in Pregnant Female Patients with Chronic Myeloid Leukemia

Updated Results from a Phase I Trial of Amulirafusp Alfa (IMM0306) in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma

Efficacy and Safety of Carfilzomib-Based Regimens in Multiple Myeloma: Single-Center Real-World Experience

Preliminary Results of Patients with Myelofibrosis (MF) from a Phase I Trial of Jab-8263, a Potent BET Inhibitor

Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China

Humanized Monoclonal Antibody IMM47, Targeting CD24, Exhibits Exceptional Anti-Tumor Efficacy By Blocking the CD24/Siglec-10 Interaction and Can be Used As Monotherapy or in Combination with Anti-PD1 Antibodies for Cancer Immunotherapy

ZGGS15, a Novel IgG4 Bispecific Monoclonal Antibody Targeting Both LAG-3 and Tigit, Demonstrates Outstanding Anti-Tumor Activity and Can be Used As Monotherapy or in Combination with Anti-PD-1 Antibodies for Cancer Immunotherapy

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Heritable SETBP1 Mutations Associated with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only